-
1
Marjan Farid appointed chair of Aurion Biotech's MAB.
-
2
She is a leading expert in cornea, cataract, and refractive surgery.
-
3
AURN001 is in Phase 3 clinical development for corneal endothelial disease.
-
4
Aurion markets a cell therapy for corneal diseases.
-
5
Farid has developed a program for severe ocular surface disease at UCI.
-
6
Aurion's vision restoration efforts aim to cure blindness from corneal diseases.
Original Source(s)
Related Content
Why Proactive Dry Eye Care Should Be the New Standard
The dental profession long ago decided it was important to preach preventative maintenance for everyone. We should do the same
by Jerry Robben
March 27, 2026
-
11 min
Busy Isn’t Predictable: The Hidden Risk in High-Performing Eye Clinics
You can look busy on paper and still run a fragile business. Predictable growth only happens when metrics, positioning, and execution are aligned
by Rod Solar
March 26, 2026
-
7 min
Layer-Specific Corneal Changes in TED
TVST study identifies diffuse stromal thinning in patients with thyroid eye disease
March 25, 2026
-
3 min
